(MedPage Today) — TORONTO — A quadruplet regimen elicited favorable outcomes in an older population of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), according to phase II trial data.
The study of daratumumab…
Source link : https://www.medpagetoday.com/meetingcoverage/ims/117573
Author :
Publish date : 2025-09-21 20:31:00
Copyright for syndicated content belongs to the linked Source.
